PDCD1 and non-small cell lung carcinoma: Interferon β and all-trans retinoic acid are important mediators of CD38 upregulation in NSCLC cells, enabling tumors to acquire resistance to anti-PD-L1 and anti-PD-1 therapy over a period of time [44].